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Abstract In humans, a first-degree family history of dementia (FH) is a well-documented risk
factor for Alzheimer’s disease (AD); however, the influence of FH on cognition across the lifespan is
poorly understood. To address this issue, we developed an internet-based paired-associates
learning (PAL) task and tested 59,571 participants between the ages of 18–85. FH was associated
with lower PAL performance in both sexes under 65 years old. Modifiers of this effect of FH on PAL
performance included age, sex, education, and diabetes. The Apolipoprotein E e4 allele was also
associated with lower PAL scores in FH positive individuals. Here we show, FH is associated with
reduced PAL performance four decades before the typical onset of AD; additionally, several
heritable and non-heritable modifiers of this effect were identified.
DOI: https://doi.org/10.7554/eLife.46179.001
Introduction
Alzheimer’s disease (AD), the leading cause of dementia, is a progressive neurodegenerative disor-
der that typically first presents clinically as deficits in cognition. It is estimated that over five million
people in the United States are currently living with AD, and by 2050, that number is expected to
climb to 13.8 million (Hebert et al., 2013). The two major risk factors for the more common late-
onset form of AD are increasing age and a first-degree family history of dementia (FH) (Braak et al.,
2011; Green et al., 2002). FH is known to encompass both heritable and nonheritable risk factors
for AD (Chang et al., 2012; Yi et al., 2018). FH has been associated with changes in multiple cogni-
tive domains previously in children (13 years old) and young adults (35 years old); however, fewer
cognitive domain changes were reported in middle-age (53 years old) and older (65–78 years old)
FH adults (Aschenbrenner et al., 2016; Bloss et al., 2008; Honea et al., 2009; La Rue et al., 2008;
Miller et al., 2005; Parra et al., 2015; Zeng et al., 2013). These effects were unrelated to the apoli-
poprotein (APOE) e4 allele. Despite these FH findings, to the authors’ knowledge, there has not
been a well-powered study of the effects of FH on memory across the lifespan. Furthermore, it is
unknown if FH status interacts with demographics, common health and APOE genotype. Identifica-
tion of factors potentiating or ameliorating an effect of FH is particularly crucial as one approach to
identifying new avenues of risk reduction for AD. Indeed, risk reduction for AD is now more critical
than ever due to the continued lack of a cure or effective disease-slowing treatments for AD
(Barnes and Yaffe, 2011; Sperling et al., 2011; Takeda and Morishita, 2018). This fact underscores
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risk reduction as one of the most practical means to attenuate the enormous burden AD places on
society (Baumgart et al., 2015).
To overcome challenges associated with underpowered studies, we created MindCrowd (www.
mindcrowd.org) as an accessible and easy-to-use web-based cognitive and demographic assess-
ment; specifically, to elucidate the effects of FH on cognition in healthy participants. Participants
were recruited across the entire adult lifespan to understand better how FH may alter cognition at
different ages. The cognitive assessment consisted of an online, verbal paired-associates learning
(PAL) task. PAL was chosen because it is a medial temporal lobe (MTL)-dependent learning and
memory task affected early in the onset of AD (Pike et al., 2008). In addition, PAL is sensitive to
changes in performance associated with healthy aging (Pike et al., 2013). Data on multiple demo-
graphic, medical, health, and lifestyle factors were also obtained (see Supplementary file 2). FH sta-
tus was determined by self-report of having (FH+), or not having (FH-) based on the question, ‘Have
you, a sibling, or one of your parents been diagnosed with Alzheimer’s disease?’ Further, a subset of
FH participants was solicited to send us dried blood spots so that we could determine their apolipo-
protein (APOE) genotype. APOE is a well-known genetic risk factor for AD. The risk of developing
AD is higher by ~6% in e4 allele carriers, while total genetic heritability risk for AD is 33% based on
single nucleotide polymorphism data (Ridge et al., 2013), and ~60–75% in twin studies
(Reynolds and Finkel, 2015). In addition, a recent study found a synergistic effect of FH and APOE
e4 on higher levels of amyloid-beta deposition measured via positron emission tomography (PET)
imaging (Yi et al., 2018). As a result of these data and numerous other reports, we hypothesized
that the APOE e4 allele would relate to lower PAL scores in FH participants.
Results
As of August 15, 2018, MindCrowd, has recruited 59,571 qualified participants (see Data Quality
Control in Materials and methods) from around the world (Figure 1A). The sample was 62.46%
female and 37.54% male (Figure 1B). An overrepresentation of women has been previously
described in studies drawn from the general population (Krokstad et al., 2013) as well as for AD
(Roberts et al., 2004). The breakdown of race was American Indian or Alaska Native = 0.62%,
Asian = 5.13%, Black/African American = 1.75%, Native Hawaiian/Pacific Islander = 0.39%,
Mixed = 0.0009%, and White = 92.03%. In terms of years of education, we collapsed across educa-
tion milestones for visualization purposes. Here we found that 10.78% reported 12 y, 29.64%
reported 14 y, 35.32%  16 y, and 24.25% reported 20 y (Figure 1C). Across the entire sample,
a FH of AD is present in 22.76% with the overall percentage swelling with age (Figure 1D).
In women and men 18–85 years old, our general linear model (GLM, see Figure 1—figure sup-
plement 1 for regression diagnostic plots and Supplementary file 1 for a table all coefficient ns)
revealed a significant Age coefficient (BAge =  0.20 word pairs, pAge <2e-16). Age was associated
with a lowered PAL performance of two word-pairs per decade of life (Figure 2). Sex was also a sig-
nificant predictor of PAL scores (BSex =  1.82, pSex <2e-16). Women were associated with nearly a
two word-pair higher PAL score compared to men (Figure 2). Propensity score matching (PSM, see
Statistical Methods in Materials and methods) revealed that the associated disparity between
women and men’s PAL scores markedly grew around the 5th decade of life. PSM revealed an esti-
mated effect size (i.e., average treatment effect among treated, ATT) of being a woman grew from
the 5th to the 6th decade of life (50 s: 2.68ATT ±0.35 SD-word pairs, 60 s: 3.72ATT ±0.32 SD-word
pairs). Educational Attainment was another significant predictor of PAL scores (BEducation = 0.31,
pEducation <2e-16, Figure 3). For both women and men, each milestone of Educational Attainment
was associated with around a third of a word pair higher PAL score. In women and men, PSM
revealed an approximate effect size of one-word pair higher performance across each level of Edu-
cational Attainment (e.g., Male 12y vs. 14y [ATT0.72 ± SD0.28], Female 12y vs. 14y=
[ATT1.06 ± SD0.24]). However, the magnitude of this effect was not consistent for men and women
across levels of Educational Attainment. Indeed, PSM estimated that women have a higher PAL
score related to education than men, at all except the highest level of Educational Attainment (16y
vs. 20y: Women=[ATT0.97 ± SD0.12], Men=[ATT1.29 ± SD0.16]).
Notably, there was a significant main effect of FH (BFH =  2.39, pFH = 3.47e-06, Figure 4A.). This
coefficient indicated that for women and men, having FH was associated with nearly a two-and-a-
half-word pair lower PAL scores when compared to FH- participants. Further our model revealed a
Talboom et al. eLife 2019;8:e46179. DOI: https://doi.org/10.7554/eLife.46179 2 of 16
Research article Human Biology and Medicine Neuroscience
significant Age x Diabetes (BAge*Diabetes = 0.03, pAge*Diabetes = 0.03) and Age x FH (BAge*FH = 0.02,
pAge*FH <0.01, Figure 4A) interaction. The significant interactions between Age and Diabetes as well
as Age and FH indicate a greater association between Diabetes and FH with lower PAL scores at
younger ages as compared to older ages. Indeed, the linear trend lines for diabetes cross at 50 years
of age (data not shown) and at age 65 for FH (Figure 4A). Due to the significant Age x FH interac-
tion, our analyses evaluating interactions with FH included only participants  65 years old. A signifi-
cant Sex x FH interaction (BSex*FH =  0.79, pSex*FH = 7.97e-06, Figure 4B) was found. Follow-up
analyses of the estimated marginal mean (EMM, see Statistical Methods in Materials and methods)
revealed that FH +women and men had lower PAL scores compared to FH- women and men
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Figure 1. Demographics of participants. (A) World map displaying a red dot (i.e., one dot = one IP address) at the
location of a participant completing the paired-associates learning (PAL) task. (B) Line plot showing the percent of
males and females from 18 to 85 years old. (C) Line plot displaying the percent of participants with 12, 14, 16, or
20 years of education for each year of age from 18 to 85 years old. (D) Line plot showing the percent of
participants reporting a first-degree family history of Alzheimer’s disease (FH) for each year of age from 18 to 85
years old.
DOI: https://doi.org/10.7554/eLife.46179.002
The following figure supplements are available for figure 1:
Figure supplement 1. Regression diagnostic plots of the general linear model (GLM) including all participants
(N=59,571).
DOI: https://doi.org/10.7554/eLife.46179.003
Figure supplement 2. Simulated additional self-report error and the impact on the significance of the FH effect in
MindCrowd.
DOI: https://doi.org/10.7554/eLife.46179.004
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(women: EMM = 1.01, t(53763) = 4.18, p<0.01; men: EMM = 1.58, t(53763) = 6.03, p<0.001); how-
ever, the magnitude of this effect was different between women and men. Indeed, PSM revealed
that the estimated word pair reduction in PAL scores associated with FH status was larger in men (e.
g., 20 s: ATT1.93 ± SD0.60) as compared to women (e.g., 20 s:ATT0.60 ± SD0.67), except for the 6
th
decade of life (60 s: Women[ATT-0.50 ± SD0.18], Men[ATT0.09 ± SD 0.36], Figure 4 Inset).
There was a significant Educational Attainment x FH interaction (BEducation*FH = 0.08, pEduca-
tion*FH <0.01). Follow-up analyses of the EMMs showed that FH was associated with lower PAL score
at each milestone of educational attainment (ts(53758) > 3.45, ps <0.01); the magnitude of the asso-
ciated decline in PAL scores attributed to FH was greater at lower milestones of educational attain-
ment as compared to higher milestones (e.g., 12y [High school diploma]: FH- EMM = 16.4,
FH +EMM = 14.8, difference = 1.6; 20y [Post graduate degree]: FH- EMM = 20.8, FH +EMM = 19.6,
difference = 1.2). In FH +or FH- women and men 18–65 years old, our model revealed a significant
FH x Diabetes (BFH*Diabetes =  0.71, pFH*Diabetes = 0.04, Figure 5) interaction. Follow-up analyses of
the EMM revealed that participants with FH and diabetes were associated with lower PAL scores
compared to participants with FH but no diabetes (FH +Diabetes + EMM = 16.9, FH +Diabetes-
EMM = 18.1, t(53763) = 2.73, p=0.03). Lastly, two models which included either: 1) the Number of
APOE e4 alleles (i.e., 0, 1, or two copies) or 2) APOE Genotype (e.g., e2-e2, e2-e3, e4-e4, etc.) were
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Figure 2. Females demonstrate enhanced paired-associates learning (PAL) performance across the aging
spectrum, and this is further enlarged beginning in the 5th decade of life. Linear regression fit (line fill ±95%
confidence interval [CI], error bars ± standard error of the mean [SEM]) of the PAL total number of correct from 18
to 85 years old. Lines were split by Sex. Women performed better than men with an amplified disparity from 50 to
70 years old (BSex =  1.82, pSex <2e-16, women n = 40572, and men n = 24381).
DOI: https://doi.org/10.7554/eLife.46179.005
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evaluated. There was a significant main effect for the Number of APOE e4 Alleles variable
(B
"4Allele =  1.30, p"4Allele = 0.02, Figure 6). These data indicated that in FH +participants, there was
an association of one and a third word pair lower PAL score per each e4 allele. Moreover, there was
a significant main effect in the model comparing the e4-e4 to the e2-e3 genotype (B
"4-"4 vs."2-"
33 5.32, p"4-"4 vs."2-"330.03). Similarly, FH +participants with the e4-e4 genotype were associated
with a five-word pair lower PAL scores compared to FH +participants with the e2-e3 genotype.
Discussion
Overall, this study finds that having a first-degree relative diagnosed with Alzheimer’s disease (FH) is
associated with lower verbal learning and memory performance (i.e., paired-associates learning;
PAL) below the age of 65. Notably, FH men showed a greater reduction in cognition compared to
FH women. This effect is not surprising since women, regardless of FH, perform better on PAL com-
pared to men (Kaushanskaya et al., 2011), an effect replicated in this study. To that end, we dem-
onstrate the sex-effect for PAL extends across the entire adult lifespan; indeed, the first time to the
authors’ knowledge that this has been demonstrated: 1) in a large cohort, 2) using the same test,
and 3) in a single study. It is interesting that our study found the associated disparity between wom-
en’s and men’s PAL scores enlarged around the 5th decade of life. The 5th decade of life is the
approximate age when women undergo menopause in developed countries. Menopause-related
changes to women’s hormonal milieu, either endogenously or via hormone treatment or gynecologi-
cal surgery have been found to alter cognition during this period (discussed in Koebele and
Bimonte-Nelson, 2016). Future studies of this cohort will dissect which medical choices at meno-
pause, and medical choices earlier in a woman’s lifespan, may underlie better preservation of verbal
memory in middle aged women as compared to men. Lastly, educational attainment was associated
with milestone-dependent higher learning and memory performance. Regardless of FH status, edu-
cation in women was associated with better PAL scores compared to men, at all except the highest
reported level of educational attainment (i.e., 16 vs. 20 years of education). The effect of education
on PAL scores is in line with observations in a clinical study demonstrating that higher levels of edu-
cation are associated with delayed AD onset (Vemuri et al., 2014; Wang et al., 2012).
In terms of health, lifestyle, and genetic factors, this study found that diabetes modified the effect
of FH on PAL. Specifically, in both women and men, diabetes and FH were associated with reduced
????????
Figure 3. Educational attainment is associated with PAL performance in a milestone-related dose response that is
different between the sexes. Linear regression fits (line fill ±95% CI, error bars ± SEM) of the PAL total number of
correct from 18 to 85 years old. Lines were split by Educational Attainment level, and the figure was faceted by
Sex. For women and men, there were heightened PAL scores per level of Educational Attainment
(BEducation = 0.31, pEducation <2e-16, 6 years n = 282, 8 years n = 181, 10 years n = 1177, 12 years n = 5367, 14 years
n = 19256, 16 years n = 22942, and 20 years n = 15752).
DOI: https://doi.org/10.7554/eLife.46179.006
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PAL performance. It is not surprising that diabetes exacerbates the effects of FH on cognition since
diabetes has been linked to worse cognitive deficits in AD (Takeda and Morishita, 2018). Several
factors may underlie this effect: 1) there are differences in the risk of dementia for type one diabetes
and type two diabetes, 2) specific type two diabetes treatments may reduce age-related declines in
neural metabolism (Hamed, 2017; Kuo et al., 2018), and 3) vascular damage may combine with
other genetic and environmental factors. As for genetic factors that modify FH, we supported our
hypothesis whereby the presence of an APOE e4 allele was associated with lower PAL performance
in a dose-dependent-like manner in FH individuals. These data suggest that APOE genotype is an
important genetic factor that influences memory. Our findings are in line with results from a voxel-
wise study in humans noting a synergistic effect of FH and the APOE e4 allele to intensify amyloid-
beta deposition and reduce glucose use in regions of the MTL and other AD-related brain regions
(Yi et al., 2018).
At the systems level, these results suggest that the collection of heritable and non-heritable
changes due to FH status alter the functioning of the MTL and associated structures (Yi et al.,
2018). The fact that these effects were only observed in participants that were 65 years old could
be due to age-related differences in the effect of FH or participation differences between younger
and older FH test takers. The 65 years old effect is partially in line with earlier smaller and more
age-specific studies of FH status and cognition demonstrating an effect of FH, but only in children
and younger adults (Bloss et al., 2008; Parra et al., 2015; Zeng et al., 2013). Since the prevalence
of AD rises after age 60, it is also possible that older FH participants consenting to our study are
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Figure 4. A first-degree relative FH of AD is associated with lower PAL performance at ages under 65. (A) Linear regression fits (line fill ±95% CI, error
bars ± SEM) of the PAL total number of correct from 18 to 85 years old. FH led to lower PAL performance before 65 years of age (BFH =  2.39,
pFH = 3.47e-06, FH +n = 14739, and FH- n = 50011). (B) Linear regression fits of the PAL total number of correct from 18 to 85 years old. Lines split by
Sex and FH status. FH led to lower PAL performance, an effect that was exacerbated in men (BSex*FH =  0.79, pSex*FH = 7.97e-06, FH +Women
n=11119, FH- Women n = 29332, FH +Men n=3617, and FH- Men n = 20678). The inset figure displays PSM box and whisker plots, split by sex, across
each decade of life. The black bar through each box and whisker plot represents the median ATT for FH. Men had worse PAL scores when compared
to women at each decade of life except for the sixth (60 s: Women[ATT-0.50 ± SD0.18], Men[ATT0.09 ± SD 0.36], women n = 40572, and men n = 24381).
DOI: https://doi.org/10.7554/eLife.46179.007
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those that have remained cognitively intact. Thus, participants that were experiencing noticeable
age- or disease-related cognitive impairment may choose not to participate.
It is important to acknowledge some limitations of our work. FH risk is known to vary depending
on the relationship of the diagnosed relative, and previous reports have demonstrated that first-
degree FH results in higher risk for dementia compared to second- and third-degree FH (Cannon-
Albright et al., 2019). In our study, we asked about the first-degree FH only; therefore, it is possible
that individuals who have other FH risk from extended family members were included in our non-FH
group. Additionally, it is possible that the form of AD, late-onset versus the rarer early-onset form,
may encode different levels of FH risk. Future work is planned to investigate the FH effect in the
study cohort, including an improved ability to separate late and early onset FH for each participant
as well as to inquire about additional extended family member FH status.
It is likely that we did not measure all demographic, lifestyle, and health factors that are associ-
ated with differential PAL performance. One such example is socioeconomic status (SES). SES has
been shown to have an association with brain structure and cognitive measures during development
(reviewed in Brito and Noble, 2014) and work also suggests SES could play a role in AD risk
(Qian et al., 2014; Ste˛pkowski et al., 2015; reviewed in Seifan et al., 2015). Importantly, while we
did not measure SES directly, we did assess factors commonly used to construct the SES composite
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Figure 5. Diabetes modified the FH effect on PAL performance. Linear regression fits (line fill ±95% CI, error
bars ± SEM) of the PAL total number of correct in FH- Diabetes+, FH +Diabetes-, and FH +Diabetes + participants
from 18 to 65 years old. Regardless of sex, diabetes in FH +participants led to lower PAL scores
(BFH*Diabetes =  0.71, pFH*Diabetes = 0.04, AD- DI- n = 47970, AD- DI +n = 2041, AD +DI n=13841, and AD +DI +
n=898).
DOI: https://doi.org/10.7554/eLife.46179.008
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(e.g., Educational Attainment). In addition, due to the international recruitment of our study cohort,
normalization of the SES construct is complicated due to differing definitions of the factors used to
calculate SES across nations (Rose et al., 2005).
Due to the large, distributed, and electronic nature of our study cohort, we rely on self-report
answers to demographic, lifestyle, and health questions. Current studies comparing self-report data
given over the internet versus in-person collected data show anywhere from a 0.3–20% discrepancy
for height and weight measurements (Maukonen et al., 2018; Nikolaou et al., 2017). To investigate
the potential role that such error may play on our FH AD effect, we re-analyzed the FH effect after
introducing additional error into the coding of the FH self-report response. Additional error was
added by randomly re-assigning FH status to various percentages of the cohort (stepwise from 2–
30% of individuals) and re-analyzing the effect of FH using our complete statistical model. This was
performed a total of 10,000 times for each error percentage, and the resulting influences on the
p-value were reported using boxplots. With 8% additional introduced error we are able to show sta-
tistically significant effect of FH on PAL in 100% of the 10,000 tested iterations while an additional
24% error in FH status would still result in a statistically significant effect of FH on PAL in over 50%
of the iterations (see Figure 1—figure supplement 2). These results suggest that it is unlikely that
FH self-report error is driving the significant effect of FH on PAL. Lastly, PAL was tested cross-
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Figure 6. Apolipoprotein E (APOE) e4 alleles negatively influence PAL performance in the presence of FH. (A)
Linear regression fits (line fill ±95% CI, error bars ± SEM) of the PAL total number of correct from 18 to 65 years
old. Lines were split by the Number of APOE e4 Alleles. For women and men, there was a dose-dependent-like
decrease in the PAL scores per each copy of the e4 allele (B
"4Allele =  1.30, p"4Allele = 0.03, e2/e2 n = 2, e2/e3
n = 31, e2/e4 n = 46, e3/e3 n = 174, e3/e4 n = 382, and e4/e4 n = 35).
DOI: https://doi.org/10.7554/eLife.46179.009
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sectionally in the cohort; therefore, determinations about the influence of collected factors on trajec-
tories of change in performance across time within an individual subject are not possible. Additional
longitudinal-based studies will be necessary to identify this class of variables.
Collectively, this study supports recommendations underscoring the importance of living a
healthy lifestyle, properly treating disease states such as diabetes, and building cognitive reserve
through education (i.e., risk reduction) to attenuate age- and AD-risk-related cognitive declines. Fur-
ther, our findings specifically highlight the positive effects of such interventions on FH-associated
risk, opening the door to the development of more targeted risk reduction approaches to combat
AD. In addition, this work underscores the utility of web-based cohort recruitment and study; thus,
facilitating large sample sizes in a cost- and time-effective fashion. Statistical power concerns are
common in many scientific studies, and underpowered study designs can lead to several potential
issues associated with false positive and negative rates. It should be acknowledged that web-based
studies are not without concerns, however, we propose that the advantage of considerably larger
sample sizes and enriched cohort diversity in online research mostly diminishes the potential
disadvantages.
Materials and methods
Key resources table
Reagent type (species)
or resource Designation Source or reference Identifiers
Additional
information
Gene (Apolipoprotein E) APOE PMCID: PMC6106945 HGNC:HGNC:613
Sequence-based
reagent
APOE PCR Primers Integrated DNA
Technologies, Inc (IDT)
F 5’-ACA-GAA-TTG-GCC
-CCG-GCC-TGG-TAC-3’,
R 5’-TAA-GCT-TGG-CAC
-GGC-TGT-CCA-AGG-A-3’
0.5 mL of each
50 mM Primer
Chemical
compound, drug
FailSafe PCR Enzyme
and 2X PreMix Buffers
Lucigen FSP995J
Chemical compound, drug HHA1 NEB R0139S 0.5 mL/20 mL of
PCR product
Other Whatman 903
Protein Saver Card
VWR 05-715-121
Chemical
compound, drug
Ultrapure Agarose Thermo 16500500 4%
Chemical
compound, drug
GelStar Gel Stain Lonza 50535 7 mL/300 mL of gel mix
Chemical
compound, drug
Ultra-Low Range
DNA Ladder
Invitrogen 10597012
Chemical
compound, drug
Amplitaq Gold Fast
Master Mix
Thermo 4390941
Chemical
compound, drug
Oragene Saliva Kit DNAGenotek OGR-500
Chemical
compound, drug
Tris-Acetate-EDTA
(TAE) 50 X (20L)
Fisher BP1332-20
Software, algorithm R The R Foundation Version 3.5.1
RRID:SCR_001905
Software, algorithm R package, ggplot2 Comprehensive R
Archive Network (CRAN)
Version 3.1.1
RRID:SCR_014601
Software, algorithm R package, emmeans Comprehensive R
Archive Network (CRAN)
Version 1.3.0
Software, algorithm R package, Zelig Comprehensive R
Archive Network (CRAN)
Version 5.1.6
Software, algorithm R package, MatchIt Comprehensive R
Archive Network (CRAN)
Version 3.0.2
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Study participants
In January 2013, Phase I began with the launch of our internet-based study site at www.mindcrowd.
org. Website visitors, who were 18 years or older, were asked to consent to our study before any
data collection via an electronic consent form. As of 8-15-2018, we have had 256,674 non-duplicate
or unique visitors to the website. Of these unique visitors, over 139,740 consented to participate.
The final data set contained 59,571 participants who completed the paired associates learning (PAL)
task and answered 22 demographic, lifestyle, and health questions (see Supplementary file 2). In
addition, 973 participants, who completed Phase I and indicated they had a first-degree relative
with Alzheimer’s disease (FH), consented to provide a self-collected biospecimen (either dried blood
or saliva) via the mail. Over 742 participants returned the biospecimen collection kits. Approval for
this study was obtained from the Western Institutional Review Board (WIRB study number 1129241).
Phase I: PAL test and demographic, medical, health, and lifestyle
questions
After consenting to the study and answering an initial five demographic questions (age, sex, years of
education, primary language, and country), participants were asked to complete a web-based
paired-associates learning (PAL) task. For this cognitive task, during the learning phase, participants
were presented 12 word-pairs, one word-pair at a time (2 s/word-pair). During the recall phase, par-
ticipants were presented with the first word of each pair and were asked to use their keyboard to
type (i.e., recall) in the missing word. This learning-recall procedure was repeated for two additional
trials. Prior to beginning the task, each participant received one practice trial consisting of three
word-pairs not contained in the 12 used during the test. Word-pairs were presented in different ran-
dom orders during each learning and each recall phase. The same word pairs and orders of presen-
tation were used for all participants. The dependent variable/criterion was the total number of
correct word pairs entered across the three trials (i.e., 12  3 = 36, a perfect score).
Upon completing the PAL task, participants were directed to a webpage asking them to fill out
an additional 17 demographic and health/disease risk factor questions. These questions included:
marital status, handedness, race, ethnicity, number of daily prescription medications, a first-degree
family history of dementia, and yes/no responses to the following: seizures, dizzy spells, loss of con-
sciousness (more than 10 min), high blood pressure, smoking, diabetes, heart disease, cancer,
stroke, alcohol/drug abuse, brain disease and/or memory problems). Next, participants were shown
their results and provided with different comparisons to other test takers based on the average
scores across all participants, as well as across sex, age, education, etc. On this same page of the
site, the participants were also provided with the option to be recontacted for future research or
not.
Phase II: Biospecimen collection
Biospecimen collection: 4961 participants who completed phase I and had a FH of AD were solicited
via email to self-collect and ship back either dried blood spots (DBS) on a 903 Protein Saver Card
(Whatman, Little Chalfont, United Kingdom) or a saliva sample using an Oragene Discover kit (DNA
Genotek Inc, Ottawa, Canada). Consenting participants (N = 973, 19.7%) were sent kits containing
easy to use instructions and everything they needed to collect, and ship DBS or stabilized saliva
back to our laboratory. Received DBS were stored at 4˚C. Participants who unable to collect enough
blood for adequate DBS were sent the saliva kit instead. For saliva, DNA was extracted and purified
as per the Oragene Discover kit’s instructions. Extracted DNA was stored at  20˚C.
Apolipoprotein E (APOE) genotyping: DBS or extracted DNA was assayed via polymerase chain
reaction (PCR, F 5’-ACA-GAA-TTG-GCC-CCG-GCC-TGG-TAC-3’, R 5’-TAA-GCT-TGG-CAC-GGC-
TGT-CCA-AGG-A-3’) and restriction fragment length polymorphism (RFLP). For DBS, PCR was per-
formed directly from a 1 mm punch of a DBS and the FailSafe PCR System using PreMix J and the
above primers (Epicentre, Madison, WI). For extracted DNA from saliva, approximately 100 ng of
DNA was added to AmpliTaq Gold Fast PCR Master Mix (Applied Biosystems: Thermo Fisher Scien-
tific, Waltham, MA) with the above primers. After PCR, for RFLP, each sample was incubated with
0.5 mL of the HhaI (New England BioLabs, Ipswich, MA) restriction enzyme for 16 hr at 37˚C. RFLP
samples were run for approximately ~4 hr at 100V on a 4% agarose gel (Invitrogen, Carlsbad, CA),
using GelStar Nucleic Acid Gel Stain (Lonza, #50535) and Ultra Low Range DNA Ladder (Invitrogen).
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Images of the gel were acquired using a Canon G15 digital (Canon, Tokyo, Japan) camera using a
DarkReader transilluminator (Clare Chemical Research Inc, Dolores, CO). APOE genotypes were
then called according to previously published methods (Oh et al., 1997). A total of 743
FH +participants were APOE genotyped. After filtering a total of 673 were used for the final analy-
ses. The variables were the presence or absence of an APOE e4 allele (Carriers vs. Non-Carriers) and
the Total Number of APOE e4 alleles (i.e., 0, 1, or 2).
Data quality control
The final dataset was filtered prior to analysis to remove participants: a) with duplicate email
addresses (only 1 st entry kept), b) who did not complete all three rounds of the PAL test, c) whose
primary language was not English, d) who was not between 18–85 years old, e) who did not report
FH status, f) who reported a history of brain disease or memory problems, and g) whose Educational
Attainment in years was not less than or equal to participants self-reported chronological age minus
four.
Statistical methods
Statistical analysis was conducted using R (version 3.5.1). For all analyses, the general linear model
(GLM)/multiple regression analysis was used to model the Total Word Pairs Correct (criterion/depen-
dent variable) as a function of our Demographic, Health, and Lifestyle Questions as well as APOE
status (predictor/independent variables). Regression fit and GLM assumptions were evaluated by
plotting residuals, testing: if these data were normally distributed, the presence of outliers and
highly influential data points, the autocorrelation of the residuals, and the presence of multicollinear-
ity (Figure 1—figure supplement 1). All measurements were taken from distinct samples. The
demographic variables used for analysis were: Age, Biological Sex, Race, Ethnicity, Educational
Attainment, Marital Status, Handedness, Number of Daily Prescription Medications, Seizures, Dizzi-
ness, Loss of Consciousness, Hypertension, Smoking, Heart Disease, Stroke, Alcohol/Drug Abuse,
Diabetes, Cancer, and FH. For APOE analyses, the variables were the Number of APOE e4 alleles
and APOE Genotype. Due to low APOE sample size (n = 519) in relation to the overall study
(N = 59,571), two GLMs (one per APOE variable), including only FH +participants, were evaluated. It
is important to note that each of the above demographic variables and indicated interaction terms
were included in every analysis unless stated otherwise due to model limitations. All plots were cre-
ated with the R package, ggplot2. Since at age 65, the FH +and FH- performance converged, pri-
mary FH modifier analyses were conducted in participants  65. Categorical by categorical
interactions were estimated using the R package, emmeans (version 1.3.0) R package. Adjustments
for multiple comparisons were evaluated using Tukey’s method via the emmeans package. Prepro-
cessing with propensity score matching (PSM) was used before statistical modeling to reduce bias
and variance (Ho et al., 2007; Ho et al., 2011). Matching was performed using the R package,
MatchIt (version 3.0.2). Effect sizes were estimated from the matched cohort using the R package,
Zelig (version 5.1.6). Zelig uses least squares regression on matched data to estimate the partial
effect on an outcome of interest, in our case, total word pairs correct (Imai et al., 2008; Imai et al.,
2009).
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